"Our IBM Choice Award winners set the bar high and consistently deliver client satisfaction and business excellence," said Marc Dupaquier, general manager, IBM Global Business Partners. "We're pleased to honor Edico Genome for continuing to uphold IBM values in pursuit of helping clients thrive in the cognitive era."
Added Pieter van Rooyen, Ph.D., chief executive officer of Edico Genome, "We heard from our customers that they wanted three things for their next-generation sequencing workflow: identical analysis whether onsite or in the cloud; scalability to meet rapidly changing needs; and security – all without requiring extensive bioinformatics expertise. In addition, one of the biggest problems we discovered is the long-term cost associated with the massive amounts of genomic data that our customers have been storing. Based on these insights we partnered with IBM to offer the DRAGEN Hybrid Cloud. IBM is in a unique position being able to offer processors, servers, storage, a public cloud and the leading cognitive computing platform in the world, IBM Watson."
For more information about the 2017 IBM Choice Awards winners, please visit https://www-304.ibm.com/partnerworld/wps/servlet/ContentHandler/pw_com_prb_beacon.
To learn more about IBM PartnerWorld, a comprehensive program that offers marketing and sales resources, training, certifications, and technical support to help create new revenue and market opportunities for IBM Business Partners, visit http://www.ibm.com/partnerworld.
About Edico Genome
The use of next-generation sequencing is growing at an unprecedented pace, creating a need for easy to implement infrastructure that enables rapid, accurate and cost-effective processing and storage of this big data. Edico Genome has created an end-to-end platform solution for analysis of next-generation sequencing data, DRAGEN™, which speeds whole genome data analysis from hours to minutes while maintaining high accuracy and reducing costs. Top clinicians and researchers are utilizing the platform to achieve faster diagnoses for critically ill newborns, cancer patients and expecting parents waiting on prenatal tests, and faster results for scientists and drug developers. For more information, visit www.EdicoGenome.com or follow @EdicoGenome.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/edico-genome-wins-2017-ibm-choice-award-for-north-america-top-independent-software-vendor-300407146.html
SOURCE Edico Genome